<![CDATA[This study aims to determine patterns of nifedipine use and analyze DRPs profiles based on the Pharmaceutical Care Network Europe (PCNE) among patients with gestational hypertension in the Inpatient Unit of Y Regional General Hospital during the 2024-2025 period. A retrospective descriptive study was conducted using the medical records of 60 patients who met the inclusion criteria. Therapeutic appropriateness was evaluated based on the 2017 National Medical Service Guidelines (PNPK) for the Management of Pregnancy Complications. The results showed that the majority were within the healthy reproductive age range of 20-35 years (61.7%), and the entire sample was in the third trimester (100%). The most common comorbid condition was anemia. Nifedipine use was dominated by a single 10 mg dose once daily (49%). A total of 28 DRPs were identified. The leading cause of DRPs was the drug selection domain (C1) in the subdomain of inappropriate drug combinations/drug interactions (C1.3), with 14 cases (50%), dominated by a pharmacosynergistic interaction between MgSO4 and nifedipine. In addition, there were 5 cases (18%) of excessively high doses (C3.2), 5 cases (18%) of too-frequent dosing regimens (C3.4), and 4 cases (14%) of too-short therapy duration (C4.1). Although nifedipine is the first-line choice, the incidence of DRPs remains quite high. Therefore, Medication Therapy Monitoring (MTM) and patient education are necessary to optimize clinical outcomes.]]>
Copyrights © 2026
